KD Logo

Cytokinetics Inc (CYTK) rating initates by RBC Capital Mkts

Cytokinetics Inc’s recently made public that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $0.37 million on Nov 12 ’24. In the deal valued at $58.48 per share,6,342 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 113,878 shares worth roughly $5.72 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, FADY MALIK bought 6,342 shares, generating $370,907 in total proceeds.

Before that, Blum Robert I sold 5,000 shares. Cytokinetics Inc shares valued at $258,150 were divested by the President & CEO at a price of $51.63 per share. As a result of the transaction, Blum Robert I now holds 397,456 shares, worth roughly $19.96 million.

RBC Capital Mkts initiated its Cytokinetics Inc [CYTK] rating to an Outperform in a research note published on November 08, 2024; the price target was $80. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. UBS also remained covering CYTK and has decreased its forecast on January 24, 2024 with a “Neutral” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 05, 2024. It rated CYTK as “an Equal-weight” which previously was an “an Overweight”.

Price Performance Review of CYTK

On Friday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -8.19% to $50.22. Over the last five days, the stock has lost -13.38%. Cytokinetics Inc shares have fallen nearly -39.85% since the year began. Nevertheless, the stocks have risen 52.97% over the past one year. While a 52-week high of $110.25 was reached on 01/08/24, a 52-week low of $30.68 was recorded on 05/28/24. SMA at 50 days reached $54.08, while 200 days put it at $60.13.

Levels Of Support And Resistance For CYTK Stock

The 24-hour chart illustrates a support level at 48.34, which if violated will result in even more drops to 46.46. On the upside, there is a resistance level at 53.62. A further resistance level may holdings at 57.02. The Relative Strength Index (RSI) on the 14-day chart is 38.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.28, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.22%. Stochastics %K at 37.38% indicates the stock is a holding.

How much short interest is there in Cytokinetics Inc?

A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2024-10-31, dropping by -1.63 million shares to a total of 15.69 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 17.32 million shares. There was a decline of -10.41%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on November 09, 2023 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.

Most Popular